La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Iovance Biotherapeutics Crescita futura

Future criteri di controllo 5/6

Si prevede che Iovance Biotherapeutics aumenterà gli utili e i ricavi rispettivamente del 66.3% e 45.6% all'anno, mentre si prevede che l'EPS crescerà del 66.5% all'anno.

Informazioni chiave

66.3%

Tasso di crescita degli utili

66.5%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	30.2%
Tasso di crescita dei ricavi	45.6%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Good
Ultimo aggiornamento	15 Aug 2024

Aggiornamenti recenti sulla crescita futura

Earnings Update: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Reported And Analysts Are Boosting Their Estimates

Aug 11

Recent updates

Earnings Update: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Reported And Analysts Are Boosting Their Estimates

Aug 11

Iovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Results

Apr 09

Iovance Biotherapeutics: Initial Amtagvi Launch In Focus

Mar 25

Iovance Biotherapeutics: Amtagvi's Pioneering Approval Sets New Standards In Melanoma

Feb 20

Iovance Biotherapeutics: Preparing For Volatility Around Lifileucel's Upcoming PDUFA Date

Jan 19

Iovance Biotherapeutics Approaches Key Regulatory Milestone As Clinical Momentum Accelerates

Sep 27

Iovance submits rolling license application to FDA for skin cancer treatment lifileucel

Aug 25

Calculating The Fair Value Of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Aug 25

Iovance Biotherapeutics falls 6% on Q2 2022 bottom line miss

Aug 04

Iovance: TIL Cell Therapy Set To Prove Itself

Jul 11

Iovance: Onward To Approval

Apr 20

Iovance Biotherapeutics: An Unproven Biopharmaceutical Company With Significant Upside

Mar 25

Iovance Biotherapeutics: Uncertainty And Opportunity

Dec 05

Previsioni di crescita degli utili e dei ricavi

NasdaqGM:IOVA - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	738	-36	31	78	9
12/31/2025	436	-247	-147	-114	13
12/31/2024	162	-371	-285	-252	12
6/30/2024	33	-440	-400	-389	N/A
3/31/2024	2	-450	-405	-384	N/A
12/31/2023	1	-444	-384	-362	N/A
9/30/2023	1	-433	-377	-356	N/A
6/30/2023	0	-419	-355	-335	N/A
3/31/2023	N/A	-412	-333	-319	N/A
12/31/2022	N/A	-396	-313	-293	N/A
9/30/2022	N/A	-390	-294	-269	N/A
6/30/2022	N/A	-376	-296	-263	N/A
3/31/2022	N/A	-358	-278	-239	N/A
12/31/2021	N/A	-342	-266	-228	N/A
9/30/2021	N/A	-311	-290	-237	N/A
6/30/2021	N/A	-284	-281	-220	N/A
3/31/2021	N/A	-265	-259	-202	N/A
12/31/2020	N/A	-260	-252	-205	N/A
9/30/2020	N/A	-255	-223	-196	N/A
6/30/2020	N/A	-246	-208	-198	N/A
3/31/2020	N/A	-230	-202	-195	N/A
12/31/2019	N/A	-198	-166	-159	N/A
9/30/2019	N/A	-167	-140	-137	N/A
6/30/2019	N/A	-151	-125	-122	N/A
3/31/2019	N/A	-134	-114	-112	N/A
12/31/2018	N/A	-124	-102	-101	N/A
9/30/2018	N/A	-117	-92	-91	N/A
6/30/2018	N/A	-105	-85	-84	N/A
3/31/2018	N/A	-98	N/A	-78	N/A
12/31/2017	N/A	-92	N/A	-79	N/A
9/30/2017	N/A	-82	N/A	-70	N/A
6/30/2017	N/A	-128	N/A	-61	N/A
3/31/2017	N/A	-116	N/A	-47	N/A
12/31/2016	N/A	-102	N/A	-33	N/A
9/30/2016	N/A	-95	N/A	-27	N/A
6/30/2016	N/A	-34	N/A	-19	N/A
3/31/2016	N/A	-29	N/A	-19	N/A
12/31/2015	N/A	-28	N/A	-18	N/A
9/30/2015	N/A	-24	N/A	-15	N/A
6/30/2015	N/A	-19	N/A	-13	N/A
3/31/2015	N/A	-15	N/A	-10	N/A
12/31/2014	N/A	-12	N/A	-9	N/A
9/30/2014	N/A	-27	N/A	-8	N/A
6/30/2014	N/A	-34	N/A	-6	N/A
3/31/2014	N/A	-35	N/A	-6	N/A
12/31/2013	N/A	-34	N/A	-4	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che IOVA diventerà redditizio nei prossimi 3 anni, il che è considerato una crescita più rapida del tasso di risparmio ( 2.5% ).

Guadagni vs Mercato: Si prevede che IOVA diventerà redditizia nei prossimi 3 anni, il che è considerato una crescita superiore alla media del mercato.

Guadagni ad alta crescita: Si prevede IOVA diventerà redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di IOVA ( 45.6% all'anno) crescerà più rapidamente del mercato US ( 8.8% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di IOVA ( 45.6% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di IOVA è previsto essere elevato tra 3 anni

Iovance Biotherapeutics Crescita futura

Future criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Earnings Update: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Reported And Analysts Are Boosting Their Estimates

Forecast to breakeven in 2026

Consensus revenue estimates increase by 11%

Price target increased by 19% to US$24.42

Consensus revenue estimates decrease by 25%

Price target decreased by 8.7% to US$20.42

Recent updates

Earnings Update: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Reported And Analysts Are Boosting Their Estimates

Iovance's Tumor-Fighting TILs Are Just Warming Up (Rating Upgrade)

Iovance Biotherapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Iovance Biotherapeutics, Inc.(NasdaqGM:IOVA) dropped from Russell 3000 Value Index

Iovance Biotherapeutics, Inc. Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma

Iovance Biotherapeutics: Amtagvi Launch Continues Upward

Iovance Biotherapeutics, Inc. Elects Frederick G. Vogt as Director

Forecast to breakeven in 2026

New minor risk - Financial position

Iovance Q1 Earnings Review: Not Enough Data To Draw Conclusions On Amtagvi

Iovance Biotherapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Iovance Biotherapeutics, Inc., Annual General Meeting, Jun 11, 2024

Iovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Results

Iovance Biotherapeutics, Inc. Agrees to A Proposed Settlement

Iovance Biotherapeutics: Initial Amtagvi Launch In Focus

Consensus revenue estimates increase by 11%

Iovance Biotherapeutics Announces Fda Has Lifted Clinical Hold on the Iov-Lun-202 Registrational Trial in Non-Small Cell Lung Cancer

New minor risk - Profitability

Iovance Biotherapeutics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

New major risk - Share price stability

Iovance Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $210.5781 million.

Price target increased by 19% to US$24.42

Iovance Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $210.5781 million.

Iovance Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $210.5781 million.

Iovance Biotherapeutics: Amtagvi's Pioneering Approval Sets New Standards In Melanoma

Consensus revenue estimates decrease by 25%

Iovance Biotherapeutics, Inc.’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma

New minor risk - Profitability

Iovance Biotherapeutics: Preparing For Volatility Around Lifileucel's Upcoming PDUFA Date

Iovance Biotherapeutics, Inc. Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer

Price target decreased by 8.7% to US$20.42

Consensus revenue estimates decrease by 71%

Iovance Biotherapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New major risk - Financial position

Independent Director recently bought US$27m worth of stock

Iovance Biotherapeutics, Inc. Announces U.S. Food and Drug Administration Updates

Price target decreased by 8.9% to US$22.36

Consensus revenue estimates decrease by 62%, EPS upgraded

New minor risk - Financial position

Iovance Biotherapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New major risk - Shareholder dilution

Iovance Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

Iovance Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

Price target increased by 13% to US$24.55

Iovance Biotherapeutics Announces First Patient Randomized in Phase 3 TILVANCE-301 Trial in Frontline Advanced Melanoma

Consensus revenue estimates decrease by 21%, EPS upgraded

Iovance Biotherapeutics, Inc. Announces U.S. Food and Drug Administration Accepts the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma

Consensus revenue estimates increase by 1,282%, EPS downgraded

Consensus revenue estimates decrease by 84%, EPS upgraded

Insufficient new directors

Consensus revenue estimates decrease by 15%, EPS upgraded

Iovance Biotherapeutics, Inc. (NasdaqGM:IOVA) entered into a definitive agreement to acquire Worldwide rights of Proleukin of Clinigen Limited fo

Interim CEO exercised options and sold US$234k worth of stock

Chief Medical Officer exercised options and sold US$67k worth of stock

Price target decreased to US$23.00

Independent Director recently bought US$62k worth of stock

Independent Director recently bought US$65m worth of stock

Price target decreased to US$23.77

Independent Director recently bought US$62k worth of stock

Iovance Biotherapeutics, Inc. Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma

Iovance Biotherapeutics, Inc. Announces Updated Clinical Data for Lifileucel in Advanced Melanoma At Society for Immunotherapy of Cancer (Sitc) Annual Meeting

Iovance Biotherapeutics, Inc. Announces Updated Clinical Data for Lifileucel in Advanced Melanoma At Society for Immunotherapy of Cancer (SITC) Annual Meeting

Iovance Biotherapeutics, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Iovance Biotherapeutics, Inc. Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte Therapy

Iovance Biotherapeutics Approaches Key Regulatory Milestone As Clinical Momentum Accelerates

Independent Director exercised options to buy US$440k worth of stock.

Iovance Biotherapeutics Initiates Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma

Iovance submits rolling license application to FDA for skin cancer treatment lifileucel

Calculating The Fair Value Of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)